Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-18T01:18:27.360Z Has data issue: false hasContentIssue false
  • English
  • Français

P-220 - Trends in Quetiapine Prescription Across Phases of Bipolar Disorder: Results From a Large Multinational Longitudinal Study (wave-bd)

Published online by Cambridge University Press:  15 April 2020

E. Vieta ,
M.L. Figueira ,
F. Bellivier ,
D. Souery ,
E. Blasco-Colmenares ,
J.M. Langosch ,
M. Moreno-Manzanaro  and
M.A. Gonzalez
E. Vieta
Affiliation:
Bipolar Disorders Programme, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain
M.L. Figueira
Affiliation:
Psychiatric Department), Hospital Santa Maria, Faculty of Medicine, University of Lisbon, Lisboa, Portugal
F. Bellivier
Affiliation:
Hôpital Henri Mondor, Pôle de Psychiatrie, Créteil Cedex, France
D. Souery
Affiliation:
Centre Européen de Psychologie Médicale / Psy-Pluriel, Bussels, Belgium
E. Blasco-Colmenares
Affiliation:
Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
J.M. Langosch
Affiliation:
Bethanien Hospital for Psychiatry, Psychosomatics, and Psychotherapy, Greifswald, Germany
M. Moreno-Manzanaro
Affiliation:
Medical Department, AstraZeneca Pharmaceuticals
M.A. Gonzalez
Affiliation:
Quintiles, Madrid, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction:

WAVE-bd addresses limitations of previous longitudinal bipolar disorder (BD) studies (mainly single disease phase- or treatment-focused).

Objectives:

To provide real-world data on BD treatment practices across countries.

Aims:

To report descriptive analyses of patients’ profiles and use of quetiapine extended and immediate release (XR and IR).

Methods:

Multicentre, non-interventional, longitudinal study of BD-I/II patients, with ≥1 mood episode in the preceding year (minimum 9 months’ follow-up). Sample was representative of BD populations from Austria, Belgium, Brazil, France, Germany, Portugal, Romania, Turkey, Ukraine and Venezuela.

Results:

During the index episode, 662/2896 (22.9%) patients took quetiapine (326 XR, 336 IR); baseline analysis of this population revealed higher incidence rates of previous hospitalisations (hospitalisations/person-year; diagnosis to study-start) in patients taking XR at index event (0.29) vs those taking IR (0.22) (p < 0.0001). Analysis of all episodes occurring during WAVE-bd in quetiapine patients revealed more frequent prescription of XR vs IR in manic (56.2% vs 43.8%) and depressive (60.5% vs 39.5%) episodes. XR prescriptions also exceeded IR prescriptions during euthymia (62.0% vs 38.0%). XR was more frequently started before, and continued after, episodes (mania: 46.5% [XR] vs 23.4% [IR], p < 0.0001; and depression: 48.1% [XR] vs 34.0% [IR], p = 0.0002). Average dose (mg/day) was higher for XR vs IR (mania: 493.7 vs 423.4 [p = 0.0194]; depression: 371.0 vs 269.0 [p < 0.0001]).

Conclusions:

Quetiapine XR and IR use differs in BD. the XR formulation appears to be prescribed more than IR, both for patients previously hospitalised more frequently, and irrespective of disease phase. AstraZeneca-funded study; Clinical Trials Registry: NCT01062607.

Type
Abstract
Information
European Psychiatry , Volume 27 , Issue S1: Abstracts of the 20th European Congress of Psychiatry , 2012 , pp. 1
Copyright
Copyright © European Psychiatric Association 2012
Submit a response

Comments

No Comments have been published for this article.